At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
ATYR1940biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
In Brief
A Phase 2 clinical trial evaluating ATYR1940 for Facioscapulohumeral Muscular Dystrophy. Completed, enrolled 9 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacioscapulohumeral Muscular Dystrophy
CountriesItaly, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedAug 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedAug 24, 2015
Enrollment StartAug 13, 2015
Primary CompletionMay 26, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.9 years ago
Interventions
ATYR1940biological
Concentrate for solution for infusion